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An uncontrolled, feasibility study of a group intervention to reduce hepatitis C 
transmission risk behaviors and increase transmission knowledge among 
women who inject drugs 
 
Abstract 
Aims. This study aimed to develop and test the feasibility, acceptability, and initial 
effectiveness of a 3-session psychosocial group intervention to reduce hepatitis C 
risk behaviours and increase hepatitis C transmission knowledge among women who 
inject drugs in five European cities/towns.  
Methods.  An uncontrolled, field effectiveness study of a psychosocial group 
intervention. Hepatitis C virus transmission knowledge, sexual and drug risk 
behaviours and depressive symptoms were assessed at baseline and one-month 
post-intervention. Intention-to-treat analyses were conducted. Findings. One-month 
post-intervention, a significant increase was reported in hepatitis C virus transmission 
knowledge and in the number of new and unused needles/syringes used to inject. 
There were significant reductions in the sharing of spoons/containers for mixing that 
had been used by someone else, sharing of filters, cookers, spoons or water with 
someone who was hepatitis C positive and the use of alcohol swabs following 
injection.   
Conclusions.The intervention showed promising results in reducing some hepatitis 
C injecting risk behaviors and increasing hepatitis C transmission knowledge among 
women who inject drugs. These preliminary findings suggest that it is feasible to 
deliver the intervention in drug treatment settings, and that the intervention was 
acceptable to both participants and staff.   
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An uncontrolled, feasibility study of a group intervention to reduce hepatitis C 
transmission risk behaviors and increase transmission knowledge among 
women who inject drugs 
 
INTRODUCTION 
In Europe the prevalence of Hepatitis C virus (HCV) is estimated at around 2-3% of 
the general population (Mohd Hanafiah et al., 2013), rising to 5-90% among people 
who inject drugs (Hahne et al., 2013).  Sharing needles/syringes and other injecting 
equipment/ paraphernalia pose the greatest risk of HCV transmission among people 
who inject drugs (Corson et al., 2013).  Many people who inject drugs have poor 
knowledge of HCV transmission (Norton et al., 2014; O'Brien et al., 2008), 
contributing to the high prevalence in this group. While there is no increased risk of 
HCV transmission in a long term, heterosexual relationship, the risk of transmission 
increases with multiple sexual partners (although this may be confounded by 
increased likelihood of injecting drug use with increased number of partners), among 
women who are infected with HIV and among men who have sex with men who are 
infected with HIV (Tohme & Holmberg, 2010). Being female is a predictor of HCV 
seropositivity (Vescio et al., 2008). One longitudinal study of young injectors found 
that females who injected drugs were more likely than males who injected to become 
infected with HCV (Tracy et al., 2014), suggesting that females may engage in 
behaviours that put them at increased risk of infection. Therefore, preventing the 
transmission of HCV among people who inject drugs, especially females, is a major 
public health challenge.  
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Increased risk of HCV among females who inject drugs 
A number of studies that have explored injecting risk behaviours in relation to blood 
borne virus transmission have highlighted the social, interpersonal and functional 
contexts in which injecting occurs (Bourgois et al., 2004; MacRae & Aalto, 2000; 
Sheard & Tompkins, 2008;  Tompkins et al., 2006).  Studies that have examined the 
injecting behaviours of women found that they report risk behaviours that include 
sharing needles, syringes and other injecting paraphernalia, having sex with people 
who inject drugs, trading sex for money or drugs and not using condoms (Booth et 
al., 1995; Brook et al., 2000; Gilchrist et al., 2011; MacRae & Aalto, 2000).  A recent 
study in England, reported that 15% of women had traded sex for money, drugs or 
other goods in the year before entering treatment for drug use (Gilchrist et al., 2015). 
Women who engage in sex trading may not use condoms with their intimate partners 
to distinguish these private relationships from sex trading (Bernstein, 2007). Women 
who inject drugs are more likely than their male counterparts to have sexual partners 
who also inject drugs and with whom they share injecting equipment (Bennett et al., 
2000; Evans et al., 2003; Gilchrist et al., 2007; Hahn et al., 2002; Stein et al., 2005; 
Wood, 2007).  Moreover, many women rely on others to inject them, often male 
sexual partners (Bryant & Treloar, 2007; Doherty et al., 2000; Hahn et al., 2002; 
MacRae & Aalto, 2000; Wood, 2007), which reduces their control over the injecting 
process (MacRae & Aalto, 2010; Tompkins et al., 2006). Studies suggest that around 
40-70% of women receiving treatment for drug misuse have experienced intimate 
partner violence (Engstrom et al., 2008; Gilchrist et al., 2011; Panchanadeswaran et 
al., 2010; Wagner et al., 2009), which may impact on their ability to insist on safer 
injecting and sexual practices (MacRae & Aalto, 2000; Wagner et al., 2009), 
potentially resulting in increased vulnerability to HCV infection. HCV risk behaviours 
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among women who inject drugs, should therefore be understood in the context of 
their relationships with male partners (Hearn et al., 2005).  The social proximity of 
other injectors has been shown to be influential on perceptions of risk. The closer the 
proximity of injecting partners/peers, the less perceived risk with sharing injecting 
equipment (MacRae & Aalto, 2000; Smyth & Roche, 2007).   Women who inject 
drugs are often marginalised and socially isolated, and as a result often engage in 
smaller social networks increasing the likelihood of sharing injecting equipment (De 
et al., 2007).  A high proportion of female drug users meet criteria for a depressive 
disorder (Torrens et al., 2011). Apathy and low mood are associated with risk 
behaviours among drug users (Gilchrist et al., 2011; Stein et al., 2005).  
 
Efficacy of interventions to reduce HCV transmission  
Most interventions to reduce injecting and sexual risk behaviours among people who 
inject drugs have targeted HIV transmission (Meader et al., 2010).  Needle and 
syringe programmes and opiate substitution treatment are effective in reducing 
injecting risk behaviours (Hagan et al., 2011), and interventions that integrate 
treatment for substance misuse with support for safe injection demonstrate the most 
efficacy for reducing HCV seroconversion (MacArthur et al., 2014).  In a systematic 
review of six behavioural interventions to prevent HCV among people who inject 
drugs, (Sacks-Davis et al., 2012) only two peer training interventions of HCV and HIV 
negative (Garfein  et al., 2007) and HCV positive (Latka et al., 2008) young injectors 
reported significantly greater reductions in injecting risk behaviours in the intervention 
group compared with the control group at 6 month follow-up. Those who tested HCV 
and HIV negative were eligible for the Third Collaborative Injection Drug Users/ Drug 
Users Intervention Trial (DUIT) (Garfein et al., 2007) and those who tested HCV 
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positive were eligible for The Study to Reduce Intravenous Exposures (STRIVE) 
(Latka et al., 2008). Both trials compared similar 6 session x 2 hour small-group, 
cognitive behavioural, skills-building interventions that taught peer education skills to 
reduce injecting (Garfein et al., 2007; Latka et al., 2008) and sexual risk behaviours 
(Garfein et al., 2007) or a video discussion group.  Among those who were HCV and 
HIV negative, the intervention group reported a 29% greater reduction in injecting risk 
behaviours than the control group, but there were no differences between trial arms 
for sexual risk behaviours (Garfein et al., 2007). Among those who were HCV 
positive, the intervention group reported a 26% greater reduction in distributive risk 
behaviours than the control group (Latka et al., 2008). The authors believe that the 
absence of gender-specific intervention content could have resulted in the lack of 
intervention effect on sexual risk behaviours for women participating in the DUIT trial 
(Mackesy-Amiti et al., 2014). They stress the need to address issues of gender 
norms, relationship power, sexual coercion, and negotiation of safer sex for reducing 
sexual risk behaviours among women who inject drugs.   Furthermore, barriers that 
can impede females who inject from accessing harm reduction services and 
information, such as stigmatisation and fear of child removal (Harris et al., 2015) 
should be addressed to ensure women can access the treatment and support they 
require.  
 
The need for gender sensitive interventions 
Despite some injecting and sexual risk practices putting women who inject drugs at 
increased risk for acquiring or transmitting HCV, none of the six trials in the Sacks-
Davis et al. (2012) review were targeted at women who inject drugs and just 24%-
46% of the participants in the included trials were female.  Gender sensitive 
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interventions should be developed and tested to address the specific risk behaviours 
for HCV transmission among women, including those related to co-occurring 
psychiatric symptoms and intimate relationships (Greenfield & Pirard, 2009). 
Moreover, women report a preference for female-only groups in drug treatment as 
they allow discussion of sensitive topics in a safe environment (Grosenick & 
Hatmaker, 2000).  The risk of sexual acquisition of HCV for HIV negative women is 
extremely low.  HCV prevention interventions for people who inject drugs may result 
in their rationalising sharing injecting equipment with a sexual partner they are having 
unprotected sex with, if they perceive an equivalent risk of HCV from both behaviours 
(Harris & Rhodes, 2013).  Interventions for women should therefore, concentrate on 
reducing injecting risk behaviours, highlight situations in which sexual transmission is 
possible (e.g. rough and anal sex where blood-to-blood contact may occur, and 
among those women who are HIV positive) and provide skills/tools to help women 
negotiate safer sexual interactions in situations that may result in increased 
transmission risk, such as intimate partner violence and sex trading. While in some 
countries (e.g. 1% in the UK) HIV prevalence among people who inject drugs 
remains low (Hope et al., 2014), trend data from the European Union highlights that 
the rate of HIV among people who inject drugs from Spain, Italy and Poland remains 
unchanged (Weissing et al., 2011), with individual studies reporting prevalence rates 
ranging from 11% in Italy (Cruciani et al., 2013) to 30% among female injectors in 
Spain (Barrio et al., 2007). Moreover, in countries such as Poland, with elevated HIV 
prevalence among people who inject drugs (18%), co-infection with HCV is reported 
to be 17% (Rosinska et al., 2015).  Therefore, the inclusion of information on safer 
sex and discussion on the increased risk of sexual transmission of HCV among 
women with HIV is warranted. 
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Aims of the study 
This study aimed to 1) adapt the US DUIT intervention (Garfein et al., 2007) for 
women; 2) test the feasibility and acceptability of delivering the adapted 
intervention in drug treatment settings in Europe; and 3) determine the initial 
effectiveness of the adapted intervention to reduce HCV risk behaviours and 
increase HCV transmission knowledge among women who inject drugs in five 
European countries.  
 
METHODS 
Design 
An uncontrolled, field effectiveness study of a manualised 3-session psychosocial 
group intervention, adapted from the DUIT intervention, with outcomes measured pre 
and one month post intervention was undertaken in 2013. 
 
Adapting the intervention 
Permission was granted by the authors of DUIT to adapt the intervention. The 
Capacity Opportunity Motivation-Behaviour framework was used to understand 
behaviour change (Michie et al., 2014) and inform the intervention adaptation.  The 
DUIT intervention was reviewed by the research team and adapted where required to 
include up-to-date information on sexual risk of HCV transmission (Franciscus, 
2015), pregnancy, motherhood and HCV transmission (Porter, 2013), and to include 
female relevant scenarios in the exercises and examples (Gilbert et al., 2006).  The 
adapted intervention highlighted the link between depression and HCV risk 
behaviours and provided participants with skills to recognise and address such 
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feelings (Carpenter et al., 2006; Carpenter et al., 2008; Gilbert et al., 2006; 
Lewinsohn et al., 1984). 
 
The intervention 
The REDUCE intervention consisted of three two-hour manualised group sessions. 
Each session began with a welcome and subsequent sessions had a brief feedback 
on what was learned in the previous session before progressing to the goals of that 
session.  In each session, participants learned about HCV transmission through 
discussion and activities. Each session included one didactic presentation from the 
group facilitator, and used games, role-play, exercises, information pamphlets, video 
and skills building approaches to enhance learning. There are many 
misunderstandings or myths surrounding HCV transmission. Session 1 
“Understanding Hepatitis C transmission risks” included a myths and facts game to 
ensure participants had up-to-date information about HCV and its transmission (e.g. 
there is no vaccination to protect against HCV, reinfection with another genotype of 
HCV is possible etc.). Thereafter, participants watched and discussed a video that 
demonstrated how cross-contamination of injecting paraphernalia could occur and 
engaged in an activity that allowed them to rate the HCV transmission risk for specific 
injecting behaviours (e.g. injecting with someone else’s used needles (higher risk) to 
use a new syringe and equipment for every injection (lower risk)). Having highlighted 
the injecting HCV transmission risks, motivation and strategies to reduce risks were 
considered (e.g. labelling your syringe to avoid inadvertent sharing). In session 2 
“Hepatitis C and sexual wellbeing – negotiating safety”, the low risk of sexual and 
mother-to-child transmission and the need to avoid pregnancy during HCV treatment 
were explained, using a rate the risk group activity. The next activity focused on why 
Page 8 of 36
URL: http:/mc.manuscriptcentral.com/cdep  Email: Torsten Kolind, tk.crf@psy.au.dk
Drugs: Education, Prevention & Policy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
9 
 
some women do things that may put them at risk of HCV (relationships and power, 
withdrawal etc.) and identified strategies/solutions and built skills and motivation to 
negotiate safer interactions with intimate partners and others. In the final session, 
“Hepatitis C and emotional wellbeing – reducing negative mood”, participants learned 
to identify symptoms of depression, understand the association between HCV 
treatment and depression, and between risk taking behaviours and depression by 
using the Behavioural Model of Depression (i.e. mood can be changed by your 
activities and the situations in which you place yourself. We can lift our mood by 
doing pleasant activities). Participants considered what they could do to change the 
way they feel and facilitators taught safer-coping skills, including the use of positive 
self-talk, for participants to use when they were feeling depressed.  The manual is 
available from the corresponding author or can be downloaded free of charge in 
English, Italian, German, Polish and Spanish from the REDUCE project website 
www.thereduceproject.imim.es (Figure 1). 
 
INSERT FIGURE 1 HERE 
 
Participants, setting and recruitment   
Females aged 18 years and older and who had injected heroin or other opiates, 
cocaine or amphetamines in the previous month were eligible to participate.  
Participants were recruited from harm reduction services (including a low 
threshold drop-in in Warsaw (Poland) where self-injecting is tolerated; injecting 
rooms in Barcelona (Spain)) and waiting rooms of drug treatment centres (health 
service and third sector providers that offered opiate substitution therapy, drug 
treatment and needle and syringe exchange) in Vienna (Austria), Ascoli Piceno 
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(Italy), Warsaw (Poland), Paisley (Scotland) and Barcelona (Spain). In addition, staff 
approached eligible participants and asked them whether they were interested in 
being contacted by a researcher to hear more about the study.  The study was 
explained to potential participants verbally by researchers and all participants were 
given an information sheet about the study prior to the researcher gaining informed 
consent.  With the exception of Warsaw, interviews were conducted by employees of 
Universities or Health Authorities. In Warsaw interviews were conducted by harm 
reduction workers, including two ex-service users. Participation was voluntary and 
participants were made aware that they could drop out of the study at any time 
without having to give a reason, and that this would not affect the care they received 
at the harm reduction or treatment centre.  
Researchers reminded participants of the intervention times and dates by 
telephone and/or text on the day before and/or on the morning of the intervention 
session they were due to attend. Participants received gift vouchers as a thank you 
for their time and travel expenses following participation in each intervention session 
and research interview.  
 
Measures 
The following outcomes were assessed at baseline (pre-intervention) and one month 
post intervention: HCV transmission knowledge, injecting and drug risk behaviours, 
condom use, and depressive symptoms.  Instruments were self-administered with 
assistance by a trained researcher where required in a private room in all sites 
except Scotland, where they were interviewer-administered. 
The HCV transmission knowledge questionnaire used in this study (REDUCE, 
2013) was adapted from Balfour et al. (Balfour et al., 2009)  and updated to include 
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gender specific questions, and questions that incorporated recent advances in sexual 
and vertical transmission (Tohme & Holmberg, 2010). The questionnaire used in the 
current study had 53 risk statements with three response options “true”, “false” and 
“don’t know”. Each correct answer scored one. The total score ranged from 0-53. The 
higher the total score, the greater the HCV transmission knowledge.  
Questions were included to determine the frequency of past month injecting 
drug use, injecting preparation and administration practices, and sexual practices to 
determine the frequency of these HCV transmission risk behaviours (University of the 
West of Scotland, 2012; Cox et al., 2008). 
The Patient Health Questionnaire (PHQ-9) (Kroenke et al., 2001) is a reliable 
and valid measure of depression severity across nine depressive symptoms 
experienced in the past two weeks as "0" (not at all) to "3" (nearly every day). A 
PHQ-9 score of 10 or more had a sensitivity of 88% and a specificity of 88% for 
major depression (Kroenke et al., 2001).  However, recent research suggests that a 
cut-off of 12 should be used for substance misusers (Delgadillo, 2012). 
 
Intervention delivery  
Following training in its use, the manualised intervention was delivered in outpatient 
drug treatment settings by a Clinical Psychologist in Austria, Italy and Spain, by two 
Health Educators in Poland, and by a blood borne virus Nurse in Scotland. The 
interventionists at each site reflected the usual way that interventions were delivered 
at these treatment settings, and therefore, real practice. A researcher attended each 
session to check the fidelity of the intervention delivered against the manual. One 
group programme of three sessions took place in each city (range 5-10 participants 
per group). 
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Analysis 
Paired t-tests were used for continuous data and McNemar tests for matched pairs 
were used for categorical data to compare pre and post intervention findings. 
Intention to treat analysis was conducted to ensure that all participants who began 
the treatment were included in the analysis, whether they completed all three 
sessions of the intervention or not. Therefore, if the participant did not complete the 
assessment one month post intervention, the responses from their baseline 
assessment were used to assume no change in their behaviour or knowledge. Such 
imputation of data was conducted for four cases at one month post intervention 
follow-up.  One question asked participants of all the needles and syringes that they 
used to inject in the last month, how many were new and unused (i.e. from a packet) 
on a scale of 0 to 10 (where 0 was none and 10 was all). A score of 10 was entered 
for the four participants that had ceased injecting at one month post intervention to 
allow for intention to treat analysis to be conducted.   
The intervention was targeted at women who had injected drugs in the past 
month regardless of their self-reported HCV status, as previous research confirms 
that people who inject drugs are not always aware of their HCV status, and that self-
reported and actual HCV status often differ (Kwiatkowski et al., 2002; O’Keefe et al., 
2013).  The analysis is therefore, not presented by HCV status. 
 
RESULTS 
Thirty six females who injected opiates or stimulant drugs in the previous month 
completed the baseline assessment with the researcher prior to beginning the 
intervention: 10 from Austria, 6 from Italy, 5 from Poland, 7 from Scotland and 8 from 
Spain (Table 1). The mean age of the participants was 32.19 years (SD 8.31; range 
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22-56 years). Most participants lived with their intimate partner (16/36; 44.4%), 
19.4% (7/36) lived alone, 19.4% (7/36) lived with friends or flatmates, 11.1% (4/36) 
lived with other family members and 8.3% (3/36) lived with their children (answers 
not mutually exclusive). The majority of participants had attained secondary school 
qualifications (20/36; 55.6%) or a technical certificate or apprentice (10/36; 27.8%). 
The majority were heterosexual (29/34; 85.3%). Almost 9% had exchanged sex for 
money, drugs or goods in the past month (3/34; 8.8%). Forty two percent (15/36; 
41.7%) reported they had ever been afraid of an intimate partner, with three (3/14; 
21.4%) participants stating they were afraid of their current intimate partner. At 
baseline the drugs that participants had injected most often in the previous month 
were heroin/other opiates (23/36; 63.9%); cocaine (9/36; 25.0%); amphetamine 
(3/36; 8.3%) and speedball (heroin and cocaine together) (1/36; 2.8%). Thirty two of 
the 36 participants reported they had ever been tested for HCV: nine self-reported 
they were HCV negative (28.1%), 18 self-reported they were HCV positive (56.3%) 
and five reported they did not know or were unwilling to disclose their HCV status 
(15.6%).  Table 1 describes the attendance at each session and attrition by country.  
 
INSERT TABLE 1 HERE 
 
Mean HCV transmission knowledge scores increased significantly from 
baseline (pre-intervention) to one month post intervention (36.44 (SD 6.81) versus 
44.97 (SD 5.74); t(35) = -7.845, p<0.001). All participants had injected drugs in the 
month prior to baseline assessment, mainly heroin (17/36; 47.2%) or other opiates 
(6/36; 16.7%), cocaine (9/36; 25.0%) or amphetamine (3/36; 8.3%). One month post 
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intervention, four participants had not injected in the month prior since the 
intervention (4/36; 11.1%).  
 
INSERT TABLE 2 
 
Participants were asked of all the needles and syringes that they used to inject in the 
last month, how many were new and unused (i.e. from a packet) on a scale of 0 to 10 
(where 0 was none and 10 was all). There was a significant increase reported in the 
number of all new and unused needles/syringes used to inject in the past month 
(Table 2).  Among the total sample (where 10 was imputed for those who had not 
injected in the month post intervention), reductions were reported in the mean 
number of times participants had injected with a needle/syringe that had already 
been used by someone else, the mean number of different people that they had 
received used needles/syringes from and the mean number of different people that 
they had passed their used needles/syringes on to from baseline to one month post 
intervention, although these reductions were not statistically significant (Table 2). 
Compared to baseline, the proportion of participants who had at one month post 
intervention used spoons or containers for mixing that had previously been used by 
someone else, used an alcohol swab when they injected drugs after the injection and 
shared filters, spoons, cookers or water with someone they knew was HCV positive 
reduced significantly. There was a marginally significant reduction in the proportion of 
participants who reported preparing drugs or rinsing their works with water that had 
already been used by someone else at one month post intervention (Table 2).  No 
reduction in condom use was reported.  For participants who reported having 
intimate relations with men and having vaginal sex in the past month (21/30; 70.0% 
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at baseline and 19/32; 59.4% at one month post intervention), 47.6% (10/21) at 
baseline and 52.6% (10/19) at one month post intervention reported they had never 
used condoms for vaginal sex during that time period.  Table 3 describes a trend 
towards greater ability to make decisions or negotiate safer drug preparation in the 
month post intervention among those who reported sharing a drug with another 
person before or after preparing it from baseline assessment.  
  
INSERT TABLE 3 
 
Depressive symptoms did not reduce significantly from baseline to one month 
post intervention (14.25 (SD 5.49) vs 14.53 (SD 6.79); t(35)= -0.313, p=0.756).  
 
Acceptability 
Feedback from staff who delivered and participants who attended the intervention 
determined its acceptability, and identified areas that worked well and those that 
could be improved. While the intervention was relatively brief (three sessions), 
professionals believed that the duration of each session (two hours) was too long for 
participants to concentrate well throughout. However, they also believed that two 
hours was too brief to be able to answer all questions raised by participants. 
Participants stated that they learned a lot and really enjoyed the interactive parts of 
the intervention including the video, games and role play exercises. They found the 
didactic sessions delivered by the professionals to be less interesting. The first 
session, Understanding Hepatitis C transmission risks, was enjoyed the most, 
followed by the second session, Hepatitis C and sexual wellbeing– negotiating 
safety. Participants felt that the strategies taught during the third session, Hepatitis C 
Page 15 of 36
URL: http:/mc.manuscriptcentral.com/cdep  Email: Torsten Kolind, tk.crf@psy.au.dk
Drugs: Education, Prevention & Policy
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
16 
 
and emotional wellbeing – reducing negative mood, were not enough to stop them 
injecting (and taking risks) when they were feeling down. This view is reflected in the 
findings that depressive symptoms did not reduce one month post-intervention. 
 
DISCUSSION 
The findings demonstrate that it was feasible and acceptable to deliver a three 
session gender specific group intervention to address HCV transmission risks in 
harm reduction and drug treatment centres in five European cities. One month post-
intervention, women’s knowledge on HCV transmission had significantly increased 
(with an average of nine additional correct answers).  However, increased knowledge 
alone does not necessarily result in corresponding changes in behaviour, therefore it 
is important that the intervention also addresses capability, opportunity and 
motivation (Michie et al., 2014). 
While there were reductions in all drug administration and preparation risk 
behaviours, only the following risk behaviours reduced significantly from pre to one 
month post-intervention: the use of spoons or containers for mixing that had 
previously been used by someone else, sharing of filters, spoons, cookers or water 
with someone who was HCV positive and the use of an alcohol swab following 
injection. There was a significant increase in the proportion of new and unused 
needles and syringes used to inject drug with.  Despite the intervention highlighting 
the possibility of becoming infected with another genotype of HCV and therefore the 
importance of not sharing injecting equipment with others regardless of their HCV 
status, the increase in the proportion sharing equipment with only those whose HIV 
or HCV status was the same as theirs was a concern and the message about this 
risk requires to be strengthened in future interventions. Conflicting results have been 
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found regarding the impact of HCV status on injecting risk behaviours.  Some studies 
report that those who knew they were HCV positive engaged in fewer HCV risk 
behaviours than those who were unaware of their status (Kwiatkowski et al., 2002), 
while other studies reported no difference (Norden, et al., 2009) or high needle 
sharing among people who were HCV positive (Korthuis et al., 2012). This may be 
due to the fact that people engage in risky injection behaviours with those they 
believe are also infected with HCV (i.e. “sero-sort) (Burt, Thiede, & Hagan, 2009), 
potentially not understanding the risks of becoming infected with another genotype of 
the virus.  While the results were not significant, greater proportions of women felt 
they were better able to control (e.g. refuse to inject because they believed the drugs 
were prepared unsafely, take the initiative of preparing the drugs, make sure drug 
preparation and injection was done safely) the preparation and administration of the 
injecting process (Table 3). 
  
 No increases in condom use were reported post-intervention, potentially due 
to 44% of participants living with an intimate partner, therefore other forms of 
contraception may be being used, or that as with many longer-term relationships 
contraception is not always used with steady partners (Mercer et al., 2013), once 
trust is established in the relationship (Gilchrist et al., 2011).    
There were no changes in depressive symptoms from pre to one month post-
intervention.  The REDUCE intervention included strategies to improve mood, and 
did not attempt to treat depression, therefore, it was perhaps unrealistic to expect any 
change in depressive symptoms.  More intensive treatment should be offered to 
women who inject drugs with comorbid depression, given the relationship between 
depressive symptoms and injecting and sexual risk behaviours (Gilchrist et al., 2011; 
Stein et al., 2005).  
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Limitations of the study 
Findings from the intervention study are limited as it was not a randomised controlled 
trial.  The small sample size could have resulted in type II errors, with insufficient 
power to account for the variation in treatment and sampling variations across sites. 
Participants were engaged with drug treatment or needle exchange services so the 
findings may not be generalizable to all women who inject drugs particularly those 
not engaged with treatment services, whose situations and experiences may be 
different. Eleven participants had also taken part in the mixed methods study so may 
have been familiar with the HCV transmission knowledge questionnaire, although 
participants in the mixed methods study were not given the correct answers to the 
questionnaire in that study.  Most sites reported that the follow-up questionnaires 
were self-completed, however where participants required help due to literacy or 
concentration issues they were assisted by the researcher.  Previous research found 
similar disclosure rates of sensitive or stigmatising information (including substance 
use) across face-to-face interview, telephone interview and paper-and-pencil 
questionnaires (Rosenbaum et al., 2006). While it is possible that participants may 
have under-reported specific behaviors to be viewed favorably by the researcher (i.e. 
social desirability), self-reports of drug use and risk behaviours have shown 
acceptable levels of reliability and validity (Darke, 1998). Despite these limitations, 
the intervention did successfully reduce some injection risk behaviours and 
significantly increased HCV transmission knowledge among women in this study. 
However, it was not successful in reducing depressive symptoms or sexual risk 
behaviours, potentially due to the fact that the intervention was not targeted at 
reducing depressive symptoms and the majority of participants may have been in 
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long term established relationships where condoms were not routinely used. As high 
proportions of women in this sample reported depressive symptoms, more intensive 
intervention should be offered to address depressive symptoms. Moreover, it may be 
unrealistic to encourage condom use in established relationships. Promising findings 
have been shown from interventions that have targeted couples who use drugs (El-
Bassel et al., 2014). “Symbiotic” goals for people who inject drugs, such as avoiding 
injecting related scars or marks and maintaining venous access, may result in the 
use of sterile injecting equipment (Harris & Rhodes, 2012).  Future harm reduction 
interventions, should focus on these symbiotic goals, and include protective practices 
and strategies to avoid injecting risk situations such as withdrawal and lack of 
preparedness (Harris et al., 2012; Mateu-Gelabert et al., 2014; Treolar et al., 2015).  
 
CONCLUSIONS 
The REDUCE intervention is an innovative, evidence-informed gender-specific group 
intervention to reduce HCV risk behaviours in the particularly vulnerable target group 
of women who inject drugs.  The study found that the intervention was both feasible 
to introduce in real world harm reduction and drug treatment services throughout 
Europe and promising findings on reducing injecting risk behaviours were reported at 
one month post-intervention.  There remains a need to update the intervention to 
incorporate recent findings on HCV prevention and determine whether these results 
can be improved.  The benefits of successful early intervention to reduce risk 
behaviours and subsequently HCV transmission, in comparison to the consecutive 
costs of treatment (from interferon to liver transplantation) highlight the importance of 
psychosocial interventions as part of a wider harm reduction strategy to reduce HCV 
among women who inject drugs. 
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Figure 1. REDUCE group intervention session content 
 
Session    Goals Content ((38) unless otherwise cited) 
1 Understanding 
Hepatitis C 
transmission 
risks 
1. Introduce the REDUCE project 
and intervention. 
2. Build group cohesion. 
3. Establish group rules. 
4. Engage participants. 
5. Increase knowledge about 
Hepatitis C and transmission 
injecting risk behaviours. 
6. Motivate participants to change 
their risk behaviours. 
1.1 Introduction and welcome  
1.2 Group rules 
1.3 Myths and facts (game) about 
Hepatitis C  
1.4 Injecting risks: cross contamination 
(video)  
1.5 Transmission risks pyramid 
(exercise)  
1.6 Strategies for reducing injection risk  
1.7 Deciding whether or not to change 
your behaviour   
1.8 Distribution of leaflet on Hepatitis C 
transmission risks and local 
resources   
1.9 Close 
   
2 Hepatitis C 
and sexual 
wellbeing – 
negotiating 
safety 
1. Increase knowledge about 
hepatitis C transmission and 
sexual well-being. 
2. Identify barriers to reducing 
sexual and injecting risk 
behaviours. 
3. Identify strategies for reducing 
hepatitis C risk with intimate 
partners and others. 
4. Increase knowledge about 
hepatitis C transmission during 
pregnancy and from mother to 
child. 
5. Motivate participants to change 
their risk behaviours. 
 
2.1 Welcome and feedback on Session 1 
2.2 Sexual transmission of Hepatitis C 
(40) 
2.3 Pregnancy, motherhood and 
Hepatitis C (41) 
2.4 Rate the risk activity 
2.5 Why do women do risky things that 
can put them at risk of Hepatitis C?  
2.6 Skills building: using TALK to 
negotiate safer sex and injection 
behaviours   
2.7 Review and close   
3 Hepatitis C 
and emotional 
wellbeing – 
reducing 
negative mood 
1. Increase knowledge about the 
association between Hepatitis 
C treatment and depression. 
2. Increase knowledge about the 
potential relationship between 
risk behaviours and negative 
mood. 
3. Identify symptoms of negative 
mood. 
4. Introduce the behavioural 
model of depression. 
5. Identify strategies for managing 
negative mood. 
6. Develop an understanding of 
self-talk and how to use it. 
7. Motivate participants to change 
their risk behaviours. 
3.1 Welcome and feedback on Session 2   
3.2 What is depression? (42) 
3.3 Understanding the link between 
depression and Hepatitis C (43) 
3.4 What can we do to change the way 
we feel? (44-46) 
3.5 The depression model (44-46) 
3.6 Skills Building: Using Safe-Coping 
and Self-Talk (42) 
3.7 Review and close   
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Table 1. Compliance and attrition by country 
 
Number attending 
each intervention session 
Number completing assessments 
at each time frame 
 1 2 3   Baseline 
(pre-  
intervention)  
One month 
post 
intervention  
Austria  10  10  10  10  8  
Italy  5*  5  5   6  6  
Poland  5  4**  3**   5  5  
Scotland  7  6  4   7  6  
Spain  8  4  6   8  7  
Total 35 29 28  36 32 
* one participant did not attend session 1 but attended session 2 (where the key 
learnings from session 1 were reviewed) and session 3 
** Sessions delivered individually to participants absent in sessions 2 and 3. 
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Table 2. Injecting risk behaviours 
In the last month....  
 
 
 
Baseline  
(pre- 
intervention)  
N=36  
One month  
post  
intervention  
N=36  
t (df) P  
 Mean (SD) Mean (SD)    
Of all needles and syringes 
used to inject in the last 
month, how many were new 
and unused (i.e. from a 
packet) on a scale of 0 to 
10 (where 0 was none and 
10 was all) 
8.44 (2.91) 9.50 (1.08) -2.14 (35) 0.040 
      
Times injected with a 
needle/ syringe that had 
already been used by 
someone else 
 
0.69 (1.95) 
 
0.36 (1.69) 1.080 (35) 0.287 
 
 
 
Number different people 
received used  
needles/syringes from 
0.33 (0.63) 0.19 (0.86) 1.405 (35) 0.169 
      
Number different people 
passed used 
needles/syringes on to 
0.28 (0.51) 0.22 (0.48)  0.627 (35) 0.535 
      
In the last month....  
 
 
 
Baseline  
(pre-intervention)  
 
N=36  
One month  
post  
intervention  
N=36  
P  
 N (%) N (%)  
Shared needles/syringes 
with someone you knew 
had HCV  
 
5 (13.9) 3 (8.5) 0.625 
Used spoons or containers 
for mixing that had 
previously been used by 
someone else 
 
18 (50.0) 8 (22.2) 0.031 
Used filters that had 
previously been used by 
someone else 
 
10 (27.8) 5 (13.9) 0.227 
Prepared drugs or rinsed 
your works with water that 
had already been used by 
someone else 
 
9 (25.0) 4 (11.1) 0.063 
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Used an alcohol swab when 
you injected drugs before 
the injection  
 
23 (63.9) 18 (50.0) 0.227 
Used an alcohol swab when 
you injected drugs after the 
injection  
 
23 (63.9) 13 (36.1) 0.006 
Shared filters, spoons, 
cookers or water with 
someone you knew was 
HCV positive  
 
10 (27.8) 4 (11.1) 0.031 
Shared a drug with another 
person before preparing it 
(i.e. divide up the drug in 
powder form)  
 
20 (55.6) 19 (52.8) 1.000 
Shared a drug with another 
person after preparing it 
(i.e. after adding water to 
make it into a solution) 
23 (63.9) 18 (50.0) 0.125 
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Table 3. Drug preparation behaviours   
 
In the last month  
 
when you shared a drug with 
another person before or after 
preparing it were you able at 
least some of the time to....  
Baseline  
(pre-  
intervention)  
N=28*  
One month  
post  
intervention  
N=27*  
p 
Take the initiative of preparing 
the drugs  
 
18 (64.3%)  21 (77.8%)  0.250 
Refuse to inject because you 
believed the drugs were prepared 
unsafely  
15 (53.6%)  19 (70.4%)  0.344 
 
Make sure drug preparation and 
injection was done safely  
 
24 (85.7%)  
 
25 (92.6%)  
 
1.000 
 
Use drugs without feeling obliged 
to share equipment  
 
22 (78.6%)  
 
23 (85.2%)  
 
1.000 
 
Tell your injecting partner how to 
prepare it and inject safely  
 
21 (75.0%)  
 
24 (88.9%)  
 
0.289 
 
Declare your hepatitis C status  
 
21 (75.0%)  
 
22 (81.5%)  
 
0.727 
 
Share equipment with only those 
whose HIV or HCV status is the 
same as yours  
 
 12 (42.9%) 
 
17 (63.0%)  
 
0.109 
  
*Analyses only conducted for those participants who reported that they had shared a 
drug with another person before or after preparing it in the last month 
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